Freestone Grove Partners’s Bio-Rad Laboratories Class A BIO Stock Holding History

Freestone Grove Partners’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$41.1M	Sell	140,113 -7,492	-5%	-$2.13M	0.26%	117
2026 Q1	$41.1M	Buy	147,605 +37,081	+34%	+$10.7M	0.29%	119
2025 Q4	$33.5M	Buy	+110,524	New	+$34.5M	0.24%	130
2025 Q3	–	Sell	-73,616	Closed	-$17.8M	–	715
2025 Q2	$17.8M	Buy	+73,616	New	+$17.4M	0.13%	213
2025 Q1	–	Sell	-46,015	Closed	-$15.1M	–	596
2024 Q4	$15.1M	Buy	+46,015	New	+$15.6M	0.19%	164

Other funds holding BIO

First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Freestone Grove Partners's BIO Position: Q2 2026 in Review

Freestone Grove Partners reduced its Bio-Rad Laboratories Class A (BIO) stake by 5.1% in Q2 2026, selling an estimated $2.13M and leaving 140,113 shares worth $41.1M. The position accounts for 0.26% of the portfolio, ranked #117.

Freestone Grove Partners first reported a position in BIO in Q4 2024 and has held it in 5 quarters since. The position peaked at $41.1M in Q1 2026. 399 funds tracked by Wall St. Rank hold BIO as of Q2 2026.

Freestone Grove Partners held 140,113 shares of Bio-Rad Laboratories Class A worth $41.1M as of Q2 2026.
Freestone Grove Partners sold 7,492 Bio-Rad Laboratories Class A shares in Q2 2026, an estimated $2.13M.
Bio-Rad Laboratories Class A made up 0.26% of Freestone Grove Partners's portfolio in Q2 2026, its #117 holding.
Freestone Grove Partners first reported a position in Bio-Rad Laboratories Class A in Q4 2024 and has held it in 5 quarters since.
Freestone Grove Partners's Bio-Rad Laboratories Class A position peaked at $41.1M in Q1 2026.
399 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2026.

Based on Freestone Grove Partners's 13F filing for Q2 2026, filed 14 Aug 2026.